PortalsOS

Pfizer's participation in TrumpRx may be motivated by the opportunity to avoid tariffs and collaborate with the administration on reducing drug costs.

Pfizer's participation in TrumpRx may be motivated by the opportunity to avoid tariffs and be part of a solution to reduce drug spending, while maintaining profitability for future innovation.

Dr. Fagenbaum emphasizes the importance of disseminating information about successful drug repurposing to ensure more patients can benefit.

It's incongruous to me that you can priority review for chemotherapy and not priority review for a biologic that is safe.

I don't understand what's happening because now we do have Bobby Kennedy in there, who is very open-minded to new solutions to old problems. Marty McCary, who's the real deal, a smart doctor running FDA.